Repligen Co. (NASDAQ:RGEN) Receives $196.70 Consensus PT from Analysts

Shares of Repligen Co. (NASDAQ:RGEN) have earned an average recommendation of “Moderate Buy” from the nine research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $196.70.

Several research firms have weighed in on RGEN. Stifel Nicolaus increased their price target on shares of Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. KeyCorp increased their price target on shares of Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th.

Insider Transactions at Repligen

In other news, Director Karen A. Dawes sold 1,000 shares of the stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total value of $193,350.00. Following the completion of the sale, the director now directly owns 87,367 shares of the company’s stock, valued at $16,892,409.45. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, VP Ralf Kuriyel sold 3,517 shares of the firm’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $193.73, for a total transaction of $681,348.41. Following the completion of the transaction, the vice president now directly owns 24,260 shares of the company’s stock, valued at $4,699,889.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Karen A. Dawes sold 1,000 shares of the firm’s stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total transaction of $193,350.00. Following the transaction, the director now directly owns 87,367 shares of the company’s stock, valued at $16,892,409.45. The disclosure for this sale can be found here. Insiders sold a total of 25,597 shares of company stock valued at $5,039,532 over the last three months. Corporate insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Repligen

A number of institutional investors and hedge funds have recently made changes to their positions in the business. State of Michigan Retirement System grew its stake in shares of Repligen by 2.4% in the 1st quarter. State of Michigan Retirement System now owns 12,753 shares of the biotechnology company’s stock worth $2,346,000 after buying an additional 300 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Repligen by 21.7% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 335,836 shares of the biotechnology company’s stock worth $61,767,000 after buying an additional 59,903 shares in the last quarter. Artemis Investment Management LLP grew its stake in shares of Repligen by 33.8% in the 1st quarter. Artemis Investment Management LLP now owns 167,813 shares of the biotechnology company’s stock worth $30,852,000 after buying an additional 42,380 shares in the last quarter. Congress Asset Management Co. MA grew its stake in shares of Repligen by 14.6% in the 1st quarter. Congress Asset Management Co. MA now owns 88,013 shares of the biotechnology company’s stock worth $16,187,000 after buying an additional 11,213 shares in the last quarter. Finally, CWM LLC grew its stake in shares of Repligen by 19.9% in the 1st quarter. CWM LLC now owns 361 shares of the biotechnology company’s stock worth $66,000 after buying an additional 60 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Stock Down 2.4 %

Shares of Repligen stock opened at $157.06 on Friday. The company has a market cap of $8.77 billion, a price-to-earnings ratio of 218.14, a price-to-earnings-growth ratio of 5.27 and a beta of 1.02. The company’s 50 day moving average is $190.02 and its 200 day moving average is $173.20. Repligen has a twelve month low of $110.45 and a twelve month high of $211.13. The company has a quick ratio of 5.75, a current ratio of 7.02 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.33. The company had revenue of $155.74 million for the quarter, compared to the consensus estimate of $155.38 million. Repligen had a net margin of 6.51% and a return on equity of 5.00%. The firm’s revenue for the quarter was down 16.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.68 earnings per share. Research analysts anticipate that Repligen will post 1.46 EPS for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.